HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1,4-cyclohexadiene

Also Known As:

cyclohexadiene

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclohexanes: 3
        Cyclohexenes: 4
        1,4-cyclohexadiene: 5

Experts

1.	Kolski-Andreaco, Aaron: 1 article (01/2007)
2.	Sabatier, Jean-Marc: 1 article (01/2007)
3.	Sankaranarayanan, Ananthakrishnan: 1 article (01/2007)
4.	Shakkottai, Vikram: 1 article (01/2007)
5.	Wulff, Heike: 1 article (01/2007)
6.	Hahn, Michael G: 1 article (10/2004)
7.	Hinz, Volker: 1 article (10/2004)
8.	Hofmann, Heiko A: 1 article (10/2004)
9.	Horváth, Ervin: 1 article (10/2004)
10.	Mauler, Frank: 1 article (10/2004)

Related Diseases

1.	Infarction (Infarctions) 10/01/2004 - "When infarct volumes were determined after 7 days, the triazole as well as the cyclohexadiene displayed strong neuroprotective efficacy (-52% infarct volume reduction at 1.2 mg/kg and -43% at 0.04 mg/kg, respectively). " 01/01/2007 - "Experiments showing that a cyclohexadiene KCa3.1 blocker reduces infarct volume in a rat subdural hematoma model further suggest KCa3.1 as a target for the treatment of traumatic and possibly ischemic brain injury. "
2.	Brain Injuries (Brain Injury) 10/01/2004 - "In the rat acute subdural haematoma model, both the triazole and cyclohexadiene displayed reduction of brain water content (-26% at 0.3 mg/kg and -24% at 0.01 mg/kg) and reduction of the intracranial pressure (-46% at 0.1 mg/kg and -60% at 0.003 mg/kg) after 24 h when administered as a 4-h infusion immediately after brain injury. " 01/01/2007 - "Experiments showing that a cyclohexadiene KCa3.1 blocker reduces infarct volume in a rat subdural hematoma model further suggest KCa3.1 as a target for the treatment of traumatic and possibly ischemic brain injury. "
3.	Endometrial Neoplasms (Endometrial Cancer) 12/01/1988 - "Twenty-six patients with measurable endometrial cancer refractory to standard therapy received AZQ [1,4-cyclohexadiene-1,4-dicarbamic acid, 2,5-bis(1-aziridinyl)3,6,dioxo,diethyl ester, NSC 182986] 22.5 mg/m2 diluted in 150 ml normal saline intravenously every three weeks. "
4.	Neoplasms (Cancer) 07/01/1983 - "These tumors were minimally responsive to the 2,5-bis(1-aziridinyl-3,6-dioxodiethyl ester of 1,4-cyclohexadiene-1,4-dicarbamic acid (NSC 182986) and cis-diamminedichloroplatinum II and unresponsive to methotrexate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido(2,3-d)pyrimidine (NSC 351521), 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC 409962), and procarbazine. "
5.	Hepatocellular Carcinoma (Hepatoma) 12/15/1989 - "Using benzenedihydrodiol [(+)-trans-1,2-dihydroxy-3,5-cyclohexadiene] as a substrate, this enzyme can be detected spectrophotometrically in rat H-4IIe hepatoma cells with a specific activity similar to that observed in rat liver cytosol. "

Related Drugs and Biologics

1.	Esters
2.	Acids
3.	diaziquone (AZQ)
4.	Triazoles
5.	Procarbazine (Matulane)
6.	Methotrexate (Mexate)
7.	Enzymes
8.	Cisplatin (Platino)
9.	Saline Solution
10.	pyrimidine

Related Therapies and Procedures

1.	Therapeutics